National Pregnancy Registry for Atypical Antipsychotics Milestone

 

We are excited to announce the enrollment of our 1000^th participant in the National Pregnancy Registry for Atypical Antipsychotics!

Formed in 2008, the Registry was established at MGH to prospectively evaluate the rates of malformations among infants exposed in utero to atypical antipsychotics. Data from the Registry thus far suggest that atypical antipsychotics as a class are not major teratogens on the order of valproic acid. The large number of participants we have been able to recruit from across the United States will allow us to (1) further refine the risk estimate for birth defects associated with atypical antipsychotics, (2) to evaluate the risk for major malformations for individual medications within the class, and (3) to look at the effect of these medicines on secondary outcomes (i.e., for gestational diabetes and NICU admission rates). Data from the Registry can help both clinicians and women trying to make treatment decisions about use of psychiatric medications during pregnancy.

We would like to thank all who have participated to date, whether by referring patients or by enrolling themselves. Gratitude is also extended to our Scientific Advisory Board and to the sponsors.

For referrals to the NPRAA or to enroll, please call the Registry toll-free at 1-866-961-2388 or email registry@womensmentalhealth.org. More information about the Registry and enrollment criteria can be found at: https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/

Lee S. Cohen, MD

Adele Viguera, MD

Marlene Freeman, MD

 

Previous Findings from the National Pregnancy Registry for Atypical Antipsychotics: 

• In Utero Exposure to Antipsychotics

• Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics, Part 1

• Evaluating the Risk of Major Malformations in Children Prenatally Exposed to Atypical Antipsychotics, Part 2

• Omega-3 Fatty Acids for Atypical Antipsychotic-Associated Hypertriglyceridemia

• Prenatal Exposure to Atypical Antipsychotics Does Not Increase Risk of Malformations

Establishment of the National Pregnancy Registry for Atypical Antipsychotics. Cohen LS, Viguera AC, McInerney KA, Kwiatkowski MA, Murphy SK, Lemon EL, Hernández-Díaz S.. The Journal of clinical psychiatry. 2015 Jul;76(7):986-9.

Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Cohen LS, Viguera AC, McInerney KA, Freeman MP, Sosinsky AZ, Moustafa D, Marfurt SP, Kwiatkowski MA, Murphy SK, Farrell AM, Chitayat D. American Journal of Psychiatry. 2015 Oct 6;173(3):263-70.

Supplement use by women during pregnancy: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Freeman MP, Sosinsky AZ, Moustafa D, Viguera AC, Cohen LS. Archives of women’s mental health. 2016 Jun 1;19(3):437-41.

Delusional Pregnancy Presenting to the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Sosinsky AZ, Freeman MP, Savella GM, Cheng LJ, Viguera AC, Cohen LS. Journal of Clinical Psychopharmacology. 2017 Jun 13.